GE HealthCare (GEHC) Q2 2026 earnings review
Record Orders Mask a Deepening Crisis in Patient Care Solutions
GE HealthCare reported an impressive 11.1% surge in organic orders, driving its backlog to a record $23.9 billion. Organic revenue grew 3.5%, matching expectations, propelled by robust execution in Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDx). However, beneath the strong top-line metrics, profitability is highly fragmented. The Patient Care Solutions (PCS) segment collapsed, with organic revenues down 13.5% and operating margins reversing to a dismal -3.8%. Consequently, total Adjusted EBIT margin compressed by 40 basis points to 14.2%. While Adjusted EPS of $1.13 represented 6.6% growth, it was aided by $0.04 in tariff refunds and a lower tax rate. The sudden departure of CFO Jay Saccaro adds execution risk as the company weighs strategic options for the struggling PCS division.
🐂 Bull Case
Organic orders accelerated massively to 11.1%, generating a book-to-bill of 1.15x. Customers are actively upgrading to new AI-enabled platforms like the Vivid Pioneer and Photonova Spectra, locking in long-term visibility.
Pharmaceutical Diagnostics grew 14.6% organically with 29.6% operating margins. Demand for contrast media is outpacing supply, giving GE HealthCare immense pricing power and insulating it from near-term generic threats.
🐻 Bear Case
Patient Care Solutions margins reversed from 9.0% in 25Q4 to -3.8% today. Operational fulfillment failures and high fixed costs are destroying value, forcing management to formally review 'strategic options' including a potential sale.
Reported Free Cash Flow of $68M looks positive, but it relies entirely on a $107M one-time tariff refund. Stripping this out, the core business burned cash in Q2 due to working capital inefficiencies and the PCS drag.
⚖️ Verdict: ⚪
Neutral. The order book is phenomenal and proves the product pipeline is winning market share. However, the catastrophic execution in PCS, heavy reliance on tariff refunds for cash flow, and an abrupt CFO exit prevent a purely bullish outlook.
Key Themes
Record Orders Precede Future Growth
Orders growth accelerated sharply from 1.1% in Q1 to 11.1% in Q2, pushing the backlog up $2.6B year-over-year to $23.9B. Management noted particular strength in long-cycle radiology equipment. Because these require room build-outs, the revenue conversion will predominantly hit in 2027, severely de-risking the company's medium-term targets.
PCS Margin Collapse and Strategic Review
The Patient Care Solutions segment is reversing course rapidly. After a disappointing 26Q1 (1.4% margin), Q2 EBIT fell to an astonishing -3.8% on a 13.5% organic revenue decline. Management cited severe operational and supply chain fulfillment challenges. The situation is dire enough that the CEO announced an active review of strategic options, explicitly mentioning a potential sale of the unit.
Pharma Diagnostics (PDx) Outperformance
PDx remains the standout performer, with organic revenue growth accelerating to 14.6% (up from 9.7% in Q1). The Vizamyl amyloid imaging agent posted strong double-digit growth, and Flyrcado doses jumped 40% from April levels. Management highlighted that global contrast demand is currently outpacing supply, providing a wide competitive moat.
Inflation Headwinds Compressing Margins
Macroeconomic pressures remain a heavy burden. The company absorbed a 120 basis point gross margin headwind in the quarter driven by memory chips, oil, and freight costs. While price actions offset some of this, overall Adjusted EBIT margins decelerated by 40 bps year-over-year. Management is banking heavily on H2 pricing mechanics to cover the ongoing $250M annual inflation drag.
Abrupt CFO Departure
Jay Saccaro's unexpected exit to leave the medical technology industry entirely introduces a layer of execution risk. He departs exactly as the company attempts to navigate a $250M inflation spike, integrate the newly combined AIS segment, and execute a potential divestiture of PCS. Interim CFO George Newcomb takes over while a search is conducted.
Software Upgrades as a High-Margin Catalyst
The 'AI Inside' strategy is materializing. GEHC reported excellent customer feedback on the True Definition DL software, an AI-powered upgrade for CT scanners that doubles image resolution on existing hardware. Sold under a subscription model, this shifts GEHC toward higher-margin, recurring software revenue rather than relying solely on capital equipment cycles.
Deteriorating Free Cash Flow Quality
While reported Free Cash Flow was $68 million, this figure includes a substantial $107 million cash inflow from an IEEPA tariff refund. Subtracting this one-time benefit reveals that the underlying business burned approximately $39 million in cash during the quarter, driven heavily by inventory build-ups ($310M headwind YTD) and the PCS segment's unprofitability.
Other KPIs
Accelerating. Sales of services grew 7.7% YoY, significantly outpacing product sales growth of 4.7%. Benefiting from both operational execution and the Intelerad acquisition, this expanding recurring revenue base provides critical stability against capital equipment cycles.
Expanding. In its first quarter operating as a combined segment (merging Imaging and AVS), AIS expanded margins by 90 basis points year-over-year despite the heavy macro inflation environment. The scale benefits of the restructure are already visible.
Guidance
Stable. The company reaffirmed its full-year outlook. Given the 3.5% growth delivered in Q2, the second half requires no heroic acceleration to meet the target, largely protected by the $23.9B backlog.
Stable. Reaffirmed after being cut in Q1. The midpoint of $4.90 implies roughly 6.7% year-over-year growth. Achieving this requires a strong step-up in H2 margins, which management expects to deliver via price increases and the normalization of PCS supply chains.
Accelerating significantly in H2. Through the first six months, the company has generated only $180M in FCF (heavily aided by tariff refunds). Achieving $1.6B requires a massive $1.4B cash generation in the back half, placing immense pressure on inventory unwinding and PCS backlog conversion.
Key Questions
Free Cash Flow Walk
Given H1 Free Cash Flow was only $180M, and that included over $100M in tariff refunds, what specific working capital levers—particularly regarding the $310M inventory build—give you confidence in hitting the $1.6B full-year guidance?
PCS Strategic Review Timeline
You've explicitly mentioned a potential sale as an outcome for the Patient Care Solutions business. What is the timeline for concluding this strategic review, and what specific financial hurdles would force a divestiture versus continuing an internal turnaround?
Order Pull-Forward Dynamics
Organic orders surged 11.1% in the quarter. With the ongoing global discussions around changing tariff policies, how much of this order strength is organic clinical demand versus hospital systems pulling forward orders to lock in pricing ahead of potential tariff hikes?